{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ADV&page=2", "query": { "intervention": "ADV", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ADV&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-13T15:22:13.425Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01533480", "title": "A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Keratoconjunctivitis Due to Adenovirus", "Viral Shedding" ], "interventions": [ { "name": "Zirgan", "type": "DRUG" }, { "name": "genteal gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lifelong Vision Foundation", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 20, "start_date": "2012-01", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2018-02-28", "last_synced_at": "2026-09-13T15:22:13.425Z", "location_count": 1, "location_summary": "Chesterfield, Missouri", "locations": [ { "city": "Chesterfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01533480" }, { "nct_id": "NCT03330197", "title": "A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pediatric Brain Tumor", "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "Ad-RTS-hIL-12", "type": "BIOLOGICAL" }, { "name": "Oral Veledimex - Arm 1 (Pediatric Brain Tumor)", "type": "DRUG" }, { "name": "Oral Veledimex - Arm 2 (DIPG)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "0 Years to 21 Years" }, "enrollment_count": 6, "start_date": "2017-09-26", "completion_date": "2021-09-10", "has_results": true, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-09-13T15:22:13.425Z", "location_count": 3, "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03330197" }, { "nct_id": "NCT04391049", "title": "Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Esophageal Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Squamous Cell Carcinoma", "Squamous Cell Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Telomerase-specific Type 5 Adenovirus OBP-301", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-12-02", "completion_date": "2030-10-06", "has_results": true, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-13T15:22:13.425Z", "location_count": 17, "location_summary": "Duarte, California • South Pasadena, California • Upland, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04391049" }, { "nct_id": "NCT03541928", "title": "Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High-risk Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "HSV-Tk", "type": "DRUG" }, { "name": "Valacyclovir", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Brachytherapy, External beam radiotherapy", "type": "RADIATION" }, { "name": "Radical prostatectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2018-08-02", "completion_date": "2023-07", "has_results": false, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-09-13T15:22:13.425Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03541928" }, { "nct_id": "NCT06999603", "title": "Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Viral Pneumonia" ], "interventions": [ { "name": "SNG001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synairgen Research Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2025-09-02", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-09-13T15:22:13.425Z", "location_count": 22, "location_summary": "Sacramento, California • Torrance, California • Naples, Florida + 19 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Naples", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Idaho Falls", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT06999603" }, { "nct_id": "NCT02661464", "title": "Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemorrhagic Fever, Ebola" ], "interventions": [ { "name": "Ad26.ZEBOV", "type": "BIOLOGICAL" }, { "name": "MVA-BN-Filo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "0 Years", "maximum_age": "71 Years", "sex": "ALL", "summary": "0 Years to 71 Years" }, "enrollment_count": 677, "start_date": "2016-05-31", "completion_date": "2021-12-13", "has_results": true, "last_update_posted_date": "2024-01-02", "last_synced_at": "2026-09-13T15:22:13.425Z", "location_count": 1, "location_summary": "Rockville, Maryland", "locations": [ { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02661464" }, { "nct_id": "NCT03339401", "title": "The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenovirus" ], "interventions": [ { "name": "Standard of Care", "type": "OTHER" }, { "name": "Brincidofovir", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Months to 25 Years" }, "enrollment_count": 29, "start_date": "2017-12-22", "completion_date": "2019-05-10", "has_results": true, "last_update_posted_date": "2021-01-25", "last_synced_at": "2026-09-13T15:22:13.425Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03339401" }, { "nct_id": "NCT03710876", "title": "Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "rAd-IFN", "type": "BIOLOGICAL" }, { "name": "Celecoxib Oral Product", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Ferring Ventures Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2019-01-21", "completion_date": "2026-01-16", "has_results": true, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-09-13T15:22:13.425Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03710876" }, { "nct_id": "NCT06125197", "title": "Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "TILT-123", "type": "BIOLOGICAL" }, { "name": "KEYTRUDA®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TILT Biotherapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2024-07-23", "completion_date": "2026-05-30", "has_results": false, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-09-13T15:22:13.425Z", "location_count": 2, "location_summary": "Newport Beach, California • Santa Monica, California", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06125197" }, { "nct_id": "NCT00849524", "title": "Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "ISF35", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Januario Castro, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2009-01", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2015-12-30", "last_synced_at": "2026-09-13T15:22:13.425Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00849524" } ] }